Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04532372 · ClinicalTrials.gov registry record · Phase 1
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04532372 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT04532372, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer. Leflunomide has been used since the 1990s as a treatment for rheumatoid arthritis. Experiments done with human cells that were given severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, showed that leflunomide was able to reduce the ability of the virus to make copies of itself. The coronavirus uses ribonucleic acid (RNA), a very long molecule that contains genetic information that is like a blueprint for making more copies of itself. Leflunomide inhibits the formation of RNA. The information gained from this study may help researchers to learn whether leflunomide is safe for use in treating patients with COVID-19, and whether it is potentially effective against the disease.
Interventions
- OTHER Best Practice
- DRUG Placebo Administration
- DRUG Leflunomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2021-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04532372
The ClinicalTrials.gov registry entry for NCT04532372 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Best Practice is the first listed.
NCT04532372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04532372 about?
NCT04532372 is a clinical study titled "Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy". This phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer. Leflunomide has been used since the 1990s as a treatment for rheumatoid arthritis. Experiments done with human cells that were given...
What is the current status of trial NCT04532372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-01-07. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT04532372?
The interventions under investigation include: Best Practice (OTHER), Placebo Administration (DRUG), Leflunomide (DRUG).
Who is sponsoring clinical trial NCT04532372?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.